Nanovaccinology: The next generation of vaccines meets 21st century materials science and engineering

Vaccine

Volumn 30, Issue 47, 2012, Pages 6609-6611

  Mamo, Tewodros ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; B LYMPHOCYTE ANTIGEN; BIOMATERIAL; DNA; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; LIPOSOME; NANOPARTICLE; PEPTIDE; PNEUMOCOCCUS VACCINE; POLYMER; T LYMPHOCYTE ANTIGEN; VACCINE; WART VIRUS VACCINE;

ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; BIOENGINEERING; CELLULAR IMMUNITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; EDITORIAL; EMULSION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGY; LARGE SCALE PRODUCTION; MAMMAL CELL; NANOTECHNOLOGY; NANOVACCINOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCIENCE; VACCINATION; VIRUS PARTICLE; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; NANOSTRUCTURES; NANOTECHNOLOGY; VACCINES; VACCINES, SUBUNIT;

EID: 84867432749     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.023     Document Type: Editorial

References (31)

1. Poland G.A., Kennedy R.B., Ovsyannikova I.G. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery?. PLoS Pathogens 2011, 7(12):e1002344.
2. Kool M., Fierens K., Lambrecht B.N. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012, 61(July(Pt 7)):927-934.
3. Mbow M.L., De G.E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22(June(3)):411-416.
4. O'Hagan D.T., De G.E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov Today 2009, 14(June(11-12)):541-551.
5. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(February(2)):145-160.
6. Burgess P., Hutt P.B., Farokhzad O.C., Langer R., Minick S., Zale S. On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol 2010, 28(December(12)):1267-1270.
7. Elsadek B., Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release 2012, 157(January(1)):4-28.
8. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(April(7291)):1067-1070.
9. Hrkach J., Von H.D., Mukkaram A.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4(4(128)):128ra39.
10. Sheridan C. Proof of concept for next-generation nanoparticle drugs in humans. Nat Biotechnol 2012, 30(June(6)):471-473.
11. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470(February(7335)):543-547.
12. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012, 109(January(4)):1080-1085.
13. Skwarczynski M., Toth I. Peptide-based subunit nanovaccines. Curr Drug Deliv 2011, 8(May(3)):282-289.
14. Fujita Y., Taguchi H. Current status of multiple antigen-presenting peptide vaccine systems: application of organic and inorganic nanoparticles. Chem Cent J 2011, 5(1):48.
15. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(June(7198)):1122-1126.
16. Demento S.L., Siefert A.L., Bandyopadhyay A., Sharp F.A., Fahmy T.M. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 2011, 29(April(6)):294-306.
17. Bandyopadhyay A., Fine R.L., Demento S., Bockenstedt L.K., Fahmy T.M. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 2011, 32(April(11)):3094-3105.
18. Demento S.L., Cui W., Criscione J.M., Stern E., Tulipan J., Kaech S.M., et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012, 33(June(19)):4957-4964.
19. Fahmy T.M., Demento S.L., Caplan M.J., Mellman I., Saltzman W.M. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond) 2008, 3(June(3)):343-355.
20. Mamo T., Moseman E.A., Kolishetti N., Salvador-Morales C., Shi J., Kuritzkes D.R., et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010, 5(February(2)):269-285.
21. Cevc G., Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J. Control. Release 2010, 141(February(3)):277-299.
22. Li H., Li Y., Jiao J., Hu H.M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 2011, 6(October(10)):645-650.
23. Dreaden E.C., Alkilany A.M., Huang X., Murphy C.J., El-Sayed M.A. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev 2012, 41(April(7)):2740-2779.
24. Rottinghaus S.T., Poland G.A., Jacobson R.M., Barr L.J., Roy M.J. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003, 21(November(31)):4604-4608.
25. dos S.T., Varela J., Lynch I., Salvati A., Dawson K.A. Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small 2011, 7(December(23)):3341-3349.
26. Duncan R., Richardson S.C. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol Pharmacol 2012, 9(September(9)):2380-2402.
27. Zuckerman J.E., Choi C.H., Han H., Davis M.E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A 2012, 109(February(8)):3137-3142.
28. Katwa P., Wang X., Urankar R.N., Podila R., Hilderbrand S.C., Fick R.B., et al. A carbon nanotube toxicity paradigm driven by mast cells and the IL-33/ST2 axis. Small 2012 Jul 6.
29. Garcia A., Mack P., Williams S., Fromen C., Shen T., Tully J., et al. Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. J Drug Deliv 2012, 2012:941243.
30. Ftouni J., Penhoat M., Addad A., Payen E., Rolando C., Girardon J.S. Highly controlled synthesis of nanometric gold particles by citrate reduction using the short mixing, heating and quenching times achievable in a microfluidic device. Nanoscale 2012, 4(August(15)):4450-4454.
31. Kim Y., Lee C.B., Ma M., Mulder W.J., Fayad Z.A., Farokhzad O.C., et al. Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. Nano Lett 2012, 12(July(7)):3587-3591.